WASHINGTON, Dec. 4, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on protocol ...

SCYNEXIS, Inc. has announced the resumption of patient dosing in the Phase 3 MARIO study of ibrexafungerp, an oral antifungal medication, following the lifting of a clinical hold by the FDA. This ...

PepGen (PEPG) shares continued to trade lower in the premarket on Thursday after the U.S. FDA placed a partial clinical hold on a mid-stage trial for PGN-EDODM1, its lead asset targeting a rare ...